<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21206864</article-id><article-id pub-id-type="pmc">2952370</article-id><article-id pub-id-type="publisher-id">IJPsy-45-234</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Olanzapine and fluoxetine combination in severe or resistant depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Haridas</surname><given-names>R.M.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Parkar</surname><given-names>S.R.</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Ghulam</surname><given-names>Ram</given-names></name><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Amin</surname><given-names>Gautam</given-names></name><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Thombre</surname><given-names>K.G.</given-names></name><xref ref-type="aff" rid="aff5"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><name><surname>Bhuvaneshwari</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="aff7"/></contrib><contrib contrib-type="author"><name><surname>Telang</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff8"/></contrib><contrib contrib-type="author"><name><surname>Obrah</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff9"/></contrib><contrib contrib-type="author"><name><surname>Toraskar</surname><given-names>Nandkishore</given-names></name><xref ref-type="aff" rid="aff10"/></contrib><contrib contrib-type="author"><name><surname>Jalali</surname><given-names>R.K.</given-names></name><xref ref-type="aff" rid="aff11"/></contrib><contrib contrib-type="author"><name><surname>Marthak</surname><given-names>Kiran V.</given-names></name><xref ref-type="aff" rid="aff12"/></contrib></contrib-group><aff id="aff1">R.M. HARIDAS, Prof. and Head, Dept of Psychiatry, Sir JJ Group of Hospitals, Mumbai</aff><aff id="aff2">S.R. PARKAR, Prof, and Head, Dept. of Psychiatry, Seth GS Medical College and KEM Hospital, Mumbai</aff><aff id="aff3">RAM GHULAM, Associated Professor and Head, Dept. of Psychiatry and Superintendent, Mahatma Gandhi Medical College, Indore</aff><aff id="aff4">GAUTAM AMIN, Consultant Psychiatrist and Psychotherapist, Dr. Contractor&#x02032;s Hospital, Vadodara</aff><aff id="aff5">K.G. THOMBRE, Consultant Psychiatrist, Ramprasad Chambers, Nana Peth, Pune</aff><aff id="aff6">A. SRIVASTAVA, Asst. Prof. of Psychiatry, Deccan College of Medical Sciences and Owaisi Hospital.and Research Centre, Hyderabad</aff><aff id="aff7">N. BHUVANESHWARI, Prof., of Psychiatry, Gandhi Hospital, Secunderabad</aff><aff id="aff8">S. TELANG, Consultant Psychiatrist, Jehangir Hospital and Medical Centre, Pune</aff><aff id="aff9">MONIKA OBRAH, Clinical Research Associate, MACR, Ranbaxy Laboratories Ltd</aff><aff id="aff10">NANDKISHORE TORASKAR, Senior Research Scientist, Clinical Data Management, Ranbaxy Laboratories Ltd</aff><aff id="aff11"><label>*</label>R.K. JALALI, Associate Director, MACR, Ranbaxy Laboratories Ltd.</aff><aff id="aff12">KIRAN V.MARTHAK, Vice President, MACR, Ranbaxy Laboratories Ltd.</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence</corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2003</year></pub-date><volume>45</volume><issue>4</issue><fpage>234</fpage><lpage>238</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>2003</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective :</title><p>The purpose of this study was to investigate the efficacy and safety of Fixed Dose Combination (FDC) of olanzapine 5 mg and fluoxetine 20 mg in Indian patients with severe or treatment resistant depression.</p></sec><sec id="st2"><title>Design :</title><p>This was an open, non-comparative study of seven weeks duration with an initial placebo run in period of one week.</p></sec><sec id="st3"><title>Method :</title><p> One hundred and fifty three patients were enrolled. One hundred and forty-four patients completed the study as per protocol and 151 patients were safety evaluable. One hundred and eleven patients (77%) received one tablet of FDC of olanzapine 5 mg / fluoxetine 20 mg once daily for 6 weeks, in patients (14%), the dose was stepped up at the end of 2 weeks to 2 tablets of FDC of olanzapine 5 mg/ fluoxetine 20 mg once daily for a further 4 weeks and 13 patients (9%) required dose to be stepped up at the end of 4 weeks to 3 tablets of FDC of olanzapine 5 mg and fluoxetine 20 mg once daily for last 2 weeks. </p></sec><sec id="st4"><title>Results :</title><p> One hundred and thirty four patients (93%) responded to FDC of olanzapine and fluoxetine therapy (a responder was defined as a patient with 50 % reduction over baseline in HDRS total score at the end of therapy).Statistically significant (p &#x0003c; 0.0001) reductions in HDRS total score, MADRS total score and CGI severity scores were seen with olanzapine/ fluoxetine combination.
One hundred and four patients (72%) were remitters (HDRS total score of &#x0003c;7) after 6 weeks of therapy.</p><p>Adverse experiences were reported by thirty one patients (20.5%). Majority of them were mild in intensity. No serious adverse event was recorded with study therapy. Three patients were withdrawn from the therapy due to adverse
event.</p></sec><sec id="st5"><title>Conclusion :</title><p> Treatment with FDC of olanzapine 5 mg / fluoxetine 20 mg was highly effective and well tolerated in Indian patients with severe or treatment resistant depression.</p></sec></abstract><kwd-group><kwd>Olanzapine</kwd><kwd>Fluoxetine</kwd><kwd>Severe depression</kwd></kwd-group></article-meta></front></article>